Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib
In this study, we present the first documented case of a patient with lung adenocarcinoma harboring a novel MIR217HG-ALK rearrangement who exhibited favorable response to neoadjuvant alectinib. Our findings suggest that alectinib holds promise as an efficacious therapeutic option for individuals with MIR217HG-ALK rearranged lung adenocarcinoma, thereby offering valuable insights for the clinical management of these patients.
Authors
- Yinyin Xue
- Kaili Huang (ORCID: https://orcid.org/0009-0006-7246-6952)
- Qinghua Zhou
- Qiang Wu (ORCID: https://orcid.org/0000-0002-5425-815X)
- Wen Li (ORCID: https://orcid.org/0000-0002-1747-9594)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.3389/fphar.2025.1602654
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sichuan University
- Natural Science Foundation of Sichuan Province
- West China Hospital, Sichuan University